JP2019528079A - 組織因子標的化抗体薬物接合体 - Google Patents
組織因子標的化抗体薬物接合体 Download PDFInfo
- Publication number
- JP2019528079A JP2019528079A JP2019511435A JP2019511435A JP2019528079A JP 2019528079 A JP2019528079 A JP 2019528079A JP 2019511435 A JP2019511435 A JP 2019511435A JP 2019511435 A JP2019511435 A JP 2019511435A JP 2019528079 A JP2019528079 A JP 2019528079A
- Authority
- JP
- Japan
- Prior art keywords
- mab
- antibody
- drug conjugate
- seq
- antibody drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 77
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 69
- 108010000499 Thromboplastin Proteins 0.000 title abstract description 86
- 102000002262 Thromboplastin Human genes 0.000 title abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims description 52
- 229940079593 drug Drugs 0.000 claims description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 230000027455 binding Effects 0.000 claims description 24
- 230000004614 tumor growth Effects 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 14
- 238000007792 addition Methods 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 9
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 9
- 206010027476 Metastases Diseases 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 7
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 7
- -1 succinimide ester Chemical class 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 108010044540 auristatin Proteins 0.000 claims description 5
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 3
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims description 3
- 208000005623 Carcinogenesis Diseases 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000036952 cancer formation Effects 0.000 claims description 3
- 231100000504 carcinogenesis Toxicity 0.000 claims description 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 3
- SLMVEZKWNOGJPD-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)butanoic acid Chemical compound OC(=O)CCCSSC1=CC=CC=N1 SLMVEZKWNOGJPD-UHFFFAOYSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 1
- 229960002317 succinimide Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 91
- 206010028980 Neoplasm Diseases 0.000 description 51
- 230000014509 gene expression Effects 0.000 description 29
- 230000012010 growth Effects 0.000 description 28
- 210000004881 tumor cell Anatomy 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 21
- 238000009739 binding Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 231100000331 toxic Toxicity 0.000 description 12
- 230000002588 toxic effect Effects 0.000 description 12
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000007822 coupling agent Substances 0.000 description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 9
- 201000002528 pancreatic cancer Diseases 0.000 description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical group O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 229960003668 docetaxel Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000002808 molecular sieve Substances 0.000 description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010070503 PAR-2 Receptor Proteins 0.000 description 5
- 102000018402 Protease-activated receptor 2 Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000011033 desalting Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000029824 high grade glioma Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- FMJUDUJLTNVWCH-UHFFFAOYSA-N 2-ethoxy-3-(4-hydroxyphenyl)propanoic acid Chemical compound CCOC(C(O)=O)CC1=CC=C(O)C=C1 FMJUDUJLTNVWCH-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000012626 DNA minor groove binder Substances 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 102100031013 Transgelin Human genes 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 238000006298 dechlorination reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- IFOHPTVCEBWEEQ-UHFFFAOYSA-N pyrrolo[2,3-i][1,4]benzodiazepine Chemical compound N1=CC=NC2=C3C=CN=C3C=CC2=C1 IFOHPTVCEBWEEQ-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108010002380 serum tumorlytic factor Proteins 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 1
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- WJQDJDVDXAAXSB-UHFFFAOYSA-N 5-sulfanylidenepyrrolidin-2-one Chemical compound O=C1CCC(=S)N1 WJQDJDVDXAAXSB-UHFFFAOYSA-N 0.000 description 1
- VGGWNGWXGFWLRK-UHFFFAOYSA-N 8,9-dihydro-1H-[1,3]oxazolo[4,5-i][1,2]benzodiazepine Chemical compound C1=CC=NNC2=C(OCN3)C3=CC=C21 VGGWNGWXGFWLRK-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003274 Arthritis viral Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 101150058540 RAC1 gene Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063544 Renal embolism Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010068067 Tumour thrombosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(a)抗体部分:及び
(b)前記抗体部分に接合される接合部分、ここで前記接合部分は検出可能マーカー、薬物、毒素、サイトカイン、放射性核種、酵素、及びそれらの組合せから成る群から選択され;
前記抗体のH鎖可能領域が、以下の3種の相補的決定領域(CDR)を含み:
(H1)配列番号1に記載の配列を有するCDR1、
(H2)配列番号2に記載の配列を有するCDR2、及び
(H3)配列番号3に記載の配列を有するCDR3;
ここで前記H鎖可能領域のアミノ酸配列のアミノ酸配列がさらに、少なくとも1つのアミノ酸の付加、欠失、修飾及び/又は置換から任意に生じ、そしてTF−結合親和性を保持する誘導体配列を含み;そして/又は
前記抗体のL鎖可変領域が、以下の3種の相補的決定領域(CDR)を含み:
(L1)配列番号4に記載の配列を有するCDR1′
(L2)配列番号5に記載の配列を有するCDR2′及び
(L3)配列番号6に記載の配列を有するCDR3′
ここで、前記アミノ酸配列中の任意のアミノ酸配列が、少なくとも1つのアミノ酸の付加、欠失、修飾及び/又は置換から生じ、そしてTF−結合親和性を有する誘導体配列を含むことを特徴とする、抗体−薬物接合体を提供する。
Dは薬物であり;そして
下付文字pは、1〜10、好ましくは1〜8から選択された値である]を有する。
(a)腫瘍細胞の移動又は転移の阻害;及び
(b)腫瘍増殖の阻害、
から成る群から選択される1又は2以上の特性を有する。
(i)第1の側面の抗体−薬物接合体、又はその組合せである活性成分;及び
(ii)医薬的に許容できる担体、
を含む医薬組成物を提供する。
本発明のネズミ抗体可変領域のヌクレオチド配列を、ヒト抗体不変領域を含む発現ベクター中にクローニングした後、動物細胞をトランスフェクトすることによりヒト−マウスキメラ抗体を発現し;
本発明のヒトFR領域を含む抗体可変領域のヌクレオチド配列を、ヒト抗体不変領域を含む発現ベクター中にクローニングした後、動物細胞をトランスフェクトすることによりヒト化抗体を発現する、工程を含む、ヒト化抗体又はキメラ抗体を調製するための方法を提供する。
本明細書において、「抗体薬物接合体」、「抗体接合体」、「抗体-薬物-接合体」、「抗体-薬物接合体」及び「免疫接合体」は相互置換可能に用いられ得、(a)抗体又は活性断片及び(b)薬物によって形成される接合体を意味する。
本明細書において使用される場合、用語「抗体(antibody)」又は「免疫グロブリン(immunoglobulin)」とは、2つの同一の軽鎖(L)及び2つの同一の重鎖(H)から成る、同じ構造特性を有する約150,000Daのヘテロテトラマー糖タンパク質である。各軽鎖は、共有ジスルフィド結合を介して重鎖に結合され、そして異なる免疫グロブリンイソタイプは、重鎖間に異なる数のジスルフィド結合を有する。各重鎖及び各軽鎖に規則的等間隔の鎖内ジスルフィド結合も存在する。各重鎖は、一端で可変領域(VH)、続いて多くの不変領域を有する。各軽鎖は、一端で可変領域(VL)及び他端で不変領域;重鎖の第1不変領域に対応する軽鎖の不変領域、及び重鎖の不変領域に対応する軽鎖の可変領域を有する。特定のアミノ酸残基は、軽鎖の可変領域と重鎖の可変領域との間に界面を形成する。
本発明は、重鎖及び軽鎖を含む、TFに対して高い特異性及び高い親和性を有する抗体を提供し、ここで重鎖は、重鎖可変領域(VH)のアミノ酸配列を含み、そして軽鎖は、軽鎖可変領域(VL)のアミノ酸配列を含む。
a1) 配列番号1;
a2) 配列番号2;
a3) 配列番号3;
a4) 配列番号4;
a5) 配列番号5;
a6) 配列番号6;
a7) 前記アミノ酸配列のいずれかのアミノ酸配列の少なくとも1つのアミノ酸の付加、欠失、修飾及び/又は置換から生じ、TF−結合親和性を有する配列。
配列番号1に記載の配列を有するCDR1、
配列番号2に記載の配列を有するCDR2、
配列番号3に記載の配列を有するCDR3;
を有し、ここで、これらのアミノ酸配列のいずれかのアミノ酸配列は、更に任意で少なくとも1つのアミノ酸の付加、欠失、修飾及び/又は置換による誘導的配列を含みつつ、TF−結合活性を保持し;
ここで、当該抗体の軽鎖可変領域は、以下の3つの相補性決定領域(CDR):
配列番号4に記載の配列を有するCDR1´、
配列番号5に記載の配列を有するCDR2´、
配列番号6に記載の配列を有するCDR3´;
を有し、ここで、これらのアミノ酸配列のいずれかのアミノ酸配列は、更に任意で少なくとも1つのアミノ酸の付加、欠失、修飾及び/又は置換による誘導的配列を含みつつ、TF−結合活性を保持している。
本発明の抗体又はそのフラグメントに対するDNA分子の配列は、従来の技法、例えばPCR増幅又はゲノムライブラリースクリーニングのような方法により得られる。さらに、軽鎖及び重鎖をコードする配列は、一緒に融合され、単鎖抗体が形成される。
本発明のADCを形成するのに用いられ得る薬物は、限定されないが:細胞毒性薬物を含む。
本発明はまた、本発明の抗体に基く抗体−薬物接合体(ADC)も提供する。
LUはリンカーであり、
Dは薬物であり;そして
下付文字pは、1〜8から選択された値である]を有する。
本発明はさらに、診断剤の製造、又はTF関連疾患を予防し、そして/又は治療するための医薬の製造のための本発明の抗体の使用を提供する。TF関連疾患は、腫瘍形成、腫瘍増殖及び/又は転移、血栓症関連疾患、炎症、代謝関連疾患などを包含する。
(i)腫瘍形成、腫瘍増殖及び/又は転移、特に高TF発現を有する腫瘍の診断、予防及び/又は治療、ここで腫瘍は以下を含む(但し、それらだけには限定されない):乳癌(例、トリプルネガティブ乳がん)、膵臓癌、肺癌、悪性神経膠腫、胃癌、肝臓癌、食道癌、腎臓癌、大腸癌、膀胱癌、前立腺癌、子宮内膜癌、卵巣癌、子宮頸癌、白血病、骨髄癌、血管肉腫など;特に、トリプルネガティブ乳癌、膵臓癌、悪性神経膠腫及び肺癌;より好ましくは、トリプルネガティブ乳癌及び/又は膵臓癌;
(ii)血栓症関連疾患の診断、予防及び/又は治療、ここで血栓症関連疾患は、以下を含む(但し、それらだけには限定されない):アテローム性動脈硬化症、急性冠症候群、急性心筋梗塞、脳卒中、高血圧、深部静脈血栓症、肺塞栓症、腎塞栓症及び動脈手術、冠状動脈バイパス術による血栓症など;
(iii)炎症の診断、予防及び/又は治療、ここで炎症は、以下を含む(但し、それらだけには限定されない):リウマチ性関節炎、変形性関節症、強直性脊椎炎、痛風、リトル症候群、乾癬性関節炎、感染性関節炎、結核性関節炎、ウイルス性関節炎、真菌性関節炎、糸球体腎炎、全身性エリテマトーデス、クローン病、潰瘍性大腸炎、急性肺損傷、慢性閉塞性肺疾患、及び特発性肺線維症;
(iv)代謝関連疾患の診断、予防及び/又は治療、ここで代謝関連疾患は、以下を含む(但し、それらだけには限定されない):糖尿病、食事性肥満、脂肪炎症など。
本発明はさらに、組成物を提供する。好ましい例によれば、組成物は、抗体、又はその活性フラグメント、融合タンパク質又はADC、又は対応するCAR−T細胞、及び医薬的に許容できる担体を含む医薬組成物である。一般的に、それらの物質は、非毒性、不活性及び医薬的に許容できる水性担体媒体において配合され得、ここでpHは一般的に約5〜8であり、好ましくは、pHは約6〜8であり、但しそのpH値は、配合される物質の性質及び治療される状態に依存して変えられ得る。配合される医薬組成物は、従来の経路、例えば腫瘍内、腹腔内、静脈内、又は局所投与(但し、それらだけには限定されない)により投与され得る。
a)本発明の抗体は、卓越した生物活性及び特性を有し、そして高い親和性を有し(EC50は、ELISAにより決定される場合、0.01〜003nMである);さらに、細胞表面TFに対して良好な結合親和性を有し、そしてTF−標的抗体として使用され得;
(b)本発明のヒト化抗体は、免疫抗体の活性に匹敵する活性を有するのみならず、また、低い免疫原性も有し;
(c)本発明の抗体及びADCの両者は、有意な抗腫瘍活性を有し、そし的哺乳類動物自体に対して明らかな毒性副作用を有さず、そして
(d)本発明の抗体及びADCは、腫瘍モデルにおいて有意な治療効果を有するのみならず、また、他の高TF発現関連疾患、例えば血栓性疾患及び代謝性疾患にも適用できる。
工程1:ハイブリドーマ細胞の調製:
最初に、生後8週の雌のBalb/cマウスを、ヒトTFタンパク質の細胞外ドメイン(UniProtKB/Swiss-Prot: P13726.1、位置34〜251からのアミノ酸)により免疫化し、ここでTFの細胞外ドメインは、免疫化された脾細胞を調製するために100μg/マウスの量で使用され;マウス骨髄腫細胞(SP2/0)及びフィーダー細胞を、融合の目的で適時に調製した。
工程1でスクリーニングされたハイブリドーマ細胞を、増幅培養にゆだねた。適応性の上昇の後、プリスタン(0.5ml/マウス)を、マウスの腹腔内に注射し、ハイブリドーマ細胞の増殖のために好ましい環境を提供した。7〜10日後、10×106個のハイブリドーマ細胞を、各マウスの腹腔内に注射した。マウスを、7日目以降、腹水及び精神状態の産生を毎日観察し、そして腹水を採取し、遠心分離し、細胞を除去し、そして後での精製のために−80℃で凍結保存した。
工程2で凍結保存された腹水を、氷上で融解し、そして0.45μmのフィルターを通して濾過した後、4℃で一晩、PBSにより透析した。最終的に、抗体を、FPLC技法により精製し、限外濾過し、所望する濃度に濃縮し、再包装し、そしてさらなる使用のために−80℃で凍結保存した。
予備スクリーニングの後、約30個のハイブリドーマを、二次限界希釈クローニングのために選択し、そして次に6個の抗体を、大規模発現及び精製のために選択した。各抗体を、フローサイトメトリーにより、ヒト乳癌細胞MDA−MB−231、ヒト膵臓癌細胞BxPC−3及びネズミ黒色腫細胞B16−F10に対するその親和性について10μg/mlの濃度で決定した。
H鎖可変領域のCDRのアミノ酸配列は、以下の通りであった:
配列番号1: SYWMN;
配列番号2: MIYPADSETRLNQKFKD;
配列番号3: EDYGSSDY。
QVQLQQPGAELVRPGASVKLSCKASGYSFISYWMNWVKQRPGQGLEWIGMIYPADSETRLNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCAREDYGSSDYWGQGTTLTVSS (配列番号7)。
配列番号4: SASSSVSYMN;
配列番号5: GISNLAS;
配列番号6: QQKSSFPWT。
EILLTQSPAIIAASPGEKVTITCSASSSVSYMNWYLQKPGSSPKIWIYGISNLASGVPARFSGSGSGTSFSFTINSMETEDVATYYCQQKSSFPWTFGGGTKLEIK(配列番号8)。
ヒト−マウス抗体を、得られた高い活性の及び特異的ネズミTF−mAb−SC1に基いて構成した。
抗体TF−mAb−SC1のH鎖可変領域(配列番号7)及びL鎖可変領域(配列番号8)の配列を参照することにより、非CDR領域と最も良く一致したヒト化鋳型を、Germlineデータベースで選択した。次に、ネズミ抗体TF−mAb−SC1のCDR領域を、選択されたヒト化鋳型に移植し、ヒト化鋳型のCDR領域を置換し、続いてIgG1/κ不変領域と組換えた。一方、ネズミ抗体の三次元構造に基いて、CDR領域と直接的に相互作用された残基、及びVL及びVHの立体配座に対する重要な効果を有した残基に対して復帰突然変異を行い、それにより、5つのヒト化H鎖可変領域(配列番号9、10、11、12及び13)及び4つのヒト化L鎖可変領域(配列番号14、15、16及び17)を得た。
TF―mAb―SC1のストック溶液に、その濃度が20mg/mlに達するまで、PBS/D(pH=7.4)緩衝液を添加し、そして次に、TF−mAb−SC1を、25℃で2時間、TCEP(2.6当量)により還元した。得られる混合物を氷上で冷却し、そしてMIMAE(6当量)を、精製しないで、直接添加した。0℃での1時間の反応の後、Cystを添加し、反応を停止した。過剰の小分子を、G25脱塩カラムにより除去し、そして得られる画分を、10mMのPBS溶液(pH7.4)に配置し、さらなる使用のために−80℃で貯蔵した。得られる抗体−薬物接合体を、TF−mAb−MMAEと命名した。
1:一段階調製
最初に、TF−mAb−SC1のストック溶液を、7.8mg/mlの最終濃度になるよう、G25脱塩カラムにより、反応緩衝液(50 mMのリン酸カリウム/50 mM のNaCl/2 mM のEDTA、pH 7.5)に交換し;そして次に、9当量の11mg/mlのMCC−DM1(DMAに溶解された;ここで反応システム中のDMA含有率は5%未満であった)を添加した。反応を、室温で6時間、実施した。遠心分離の後、上清液を、Qカラム及びカチオンカラム精製により精製し、過剰の小分子を除去し、そして最終的に、G25脱塩化ラム又は限外濾過により、10mMのPBS溶液に交換し、そしてさらなる使用のために−80℃で貯蔵した。得られた抗体−薬物接合体を、TF−mAb−DM1と命名した。
TF−mAb−SC1のストック溶液を、10mg/mlの最終濃度になるよう、G25脱塩カラムにより、反応緩衝液(50 mMのリン酸カリウム/50 mM のNaCl/2 mM のEDTA、pH 7.5)に交換し;そして次に、8当量のMCC−DM(DMAOに溶解された)を添加した。反応を、10−12℃で3時間、実施した、そして過剰SMCCを、G25脱塩カラムにより除去した。DM1(12当量)を、P−MCCに添加し、そして反応を25℃で18時間、行い、そして最終的に、G25脱塩化ラムにより、10mMのPBS溶液に交換し、そしてさらなる使用のために−80℃で貯蔵した。得られた抗体−薬物接合体を、TF−mAb−DM1と命名した。
この実施例に使用される以下の細胞系を、American Type Culture Collection (ATCC) 又は Cell Bank of Chinese Academy of Sciencesから購入し、そしてその対応する説明書に従って培養した:MCF7、MDA−453、T47D、A549、U87MG、H1975、MDA−MB−231、BxPC−3、HCC1806及び Hs578T。
細胞生存率=ODadministration −ODblank)/(ODcontrol-ODblank)×100%
対数増殖期におけるHCC1806及びBxPC−3細胞を、生後6週のBalb/c雌ヌードマウスの背の皮下又は乳房脂肪パッドに、それぞれ200μlの無血清培地当たり3×106及び10×106個の密度で接種するために使用した(Balb/cヌードは、Shanghai Xipuer-Beikai Experimental Animal Co., Ltd.から購入された)。腫瘍が100〜200mm3まで増殖した後、動物をランダムにグループ分けし、各グループについて8個の腫瘍を有した。マウスに、3.75mg/kg及び15mg/kgの用量でTF−mAb−DM1を投与するか、0.7mg/kg、2mg/kg、3.75mg/kg、7mg/kg及び15mg/kgの用量でTF−mAb−MMAEを、尾の静脈に週当たり1度、投与した。正常マウスIgG(IgG)及びドセタキセルを、それぞれ、負及び正の対照薬物として使用した。ヌードマウスの腫瘍体積及び重量を、週当たり2〜3度、測定し、そして記録し、腫瘍増殖曲線をプロットした。腫瘍体積(V)を、以下の式に従って計算した:
V=1/2×a×b2
式中、a及びbは、それぞれ、腫瘍の長さ及び幅を表している。
実施例4−7を反復し、但しTF−mAb−SC1を、以下により置換した:TF−mAb−H29、 TF−mAb−H30、 TF−mAb−H31、 TF−mAb−H32、 TF−mAb−H33、 TF−mAb−H34、 TF−mAb−H35、 TF−mAb−H36、 TF−mAb−H37、 TF−mAb−H38、 TF−mAb−H39、 TF−mAb−H40、 TF−mAb−H41、 TF−mAb−H42、 TF−mAb−H43、 TF−mAb−H44、 TF−mAb−H45、 TF−mAb−H46、 TF−mAb−H47、及びTF−mAb−H48。
Claims (10)
- 抗体薬物接合体であって、以下:
(a)抗体部分;及び
(b)当該抗体部分と接合した接合部分、ここで当該接合部分は、検出マーカー、薬物、毒素、サイトカイン、放射性核種、酵素及びそれらの組合せからなる群から選択される;
を含み、当該抗体の重鎖可変領域が、以下の3つの相補性決定領域(CDR):
(H1)配列番号1に記載の配列を有するCDR1;
(H2)配列番号2に記載の配列を有するCDR2;及び
(H3)配列番号3に記載の配列を有するCDR3;
を含み、ここで、当該重鎖可変領域のアミノ酸配列のいずれかが、更に、任意で1つ以上のアミノ酸の付加、欠失、変更及び/又は置換による派生配列を含み、そしてTF結合活性を保持し;及び/又は
当該抗体の軽鎖可変領域が、以下の3つの相補性決定領域(CDR):
(L1)配列番号4に記載の配列を有するCDR1';
(L2)配列番号5に記載の配列を有するCDR2';及び
(L3)配列番号6に記載の配列を有するCDR3';
を含み、ここで、当該軽鎖可変領域のアミノ酸配列のいずれかが、更に、任意で1つ以上のアミノ酸の付加、欠失、変更及び/又は置換による派生配列を含み、そしてTF結合活性を保持する、抗体薬物接合体。 - 前記抗体薬物接合体(ADC)が、以下の式:
Abは抗TF抗体であり、
LUはリンカーであり、
Dは薬物であり、
Pは1〜10、好ましくは1〜8から選択される数値である)
で表される、請求項1に記載の抗体薬物接合体。 - LUが:6-マレイミドカプロイル-バリン-シトルリン-p−アミノベンジルオキシカルボニル(MC-val-cit-PAB)、6-マレイミドカプロイル-アラニン-フェニルアラニン-p−アミノベンジルオキシカルボニル(MC-ala-phe-PAB)、マレイミドプロピオニル-バリン-シトルリン-p−アミノベンジルオキシカルボニル(MP-val-cit-PAB)、マレイミドプロピオニル-アラニン-フェニルアラニン-p−アミノベンジルオキシカルボニル(MP-ala-phe-PAB)、N-スクシニミジル4-(2-ピリジルチオ)ペンタノエート(SPP)、N-スクシニミジル4-(N-マレイミドメチル)シクロヘキサン-1-カルボキシレート(SMCC)、4-(2-ピリジルジチオ)ブタン酸N-ヒドロスクシニミドエステル(SPDB)又はN-スクシニミジル(4-ヨード-アセチル)アミノベンゾエート(SIAB)からなる群から選択される、請求項2に記載の抗体薬物接合体。
- Dが:
(i)マイタジン(Maytansine)誘導体(DM1、DM4)、アウリスタチン(auristatin)及び(dolastatin);並びに
(ii)モノメチルアウリスタチンE(MMAE)、モノメチルアウリスタチンF(MMAF)、モノメチルドラスタチン10(MMAD)誘導体又はそれらの組合せ;
からなる群から選択される、請求項2に記載の抗体薬物接合体。 - 前記抗体が、以下:動物由来の抗体、キメラ抗体、ヒト化抗体、又はそれらの組合せから選択される、請求項1に記載の抗体薬物接合体。
- 前記抗体の重鎖可変領域の配列が、以下:配列番号7、9、10、11、12、又は13からなる群から選択され;及び/又は
前記抗体の軽鎖可変領域の配列が、以下:配列番号8、14、15、16、又は17からなる群から選択される、請求項1に記載の抗体薬物接合体。 - 前記抗体が、以下:TF-mAb-SC1、TF-mAb-Ch、TF-mAb-H29、TF-mAb-H30、TF-mAb-H31、TF-mAb-H32、TF-mAb-H33、TF-mAb-H34、TF-mAb-H35、TF-mAb-H36、TF-mAb-H37、TF-mAb-H38、TF-mAb-H39、TF-mAb-H40、TF-mAb-H41、TF-mAb-H42、TF-mAb-H43、TF-mAb-H44、TF-mAb-H45、TF-mAb-H46、TF-mAb-H47、及びTF-mAb-H48の群から選択される、請求項1に記載の抗体薬物接合体。
- 前記抗体が、(i)診断剤の製造;及び/又は(ii)TF関連疾患の予防及び/又は治療用医薬の製造に使用される、請求項1に記載の抗体薬物接合体の使用。
- 前記TF関連疾患が:腫瘍形成、腫瘍成長及び/又は転移からなる群から選択される、請求項8に記載の使用。
- 以下:
(i)請求項1に記載の抗体薬物接合体又はその組合せである有効成分;及び
(ii)医薬として許容される担体;
を含有する、医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610704559 | 2016-08-22 | ||
CN201610704559.1 | 2016-08-22 | ||
CN201710125244.6A CN106938051B (zh) | 2016-08-22 | 2017-03-03 | 靶向于组织因子的抗体-药物偶联物 |
CN201710125244.6 | 2017-03-03 | ||
PCT/CN2017/087779 WO2018036243A1 (zh) | 2016-08-22 | 2017-06-09 | 靶向于组织因子的抗体-药物偶联物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019528079A true JP2019528079A (ja) | 2019-10-10 |
JP7020655B2 JP7020655B2 (ja) | 2022-02-16 |
Family
ID=59469529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019511435A Active JP7020655B2 (ja) | 2016-08-22 | 2017-06-09 | 組織因子標的化抗体薬物接合体 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11534495B2 (ja) |
EP (1) | EP3501548A4 (ja) |
JP (1) | JP7020655B2 (ja) |
CN (1) | CN106938051B (ja) |
WO (1) | WO2018036243A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210177987A1 (en) * | 2017-11-02 | 2021-06-17 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
CN108226531A (zh) * | 2017-12-27 | 2018-06-29 | 三诺生物传感股份有限公司 | 一种β2-微球蛋白检测试剂盒 |
CN110141666B (zh) * | 2018-02-13 | 2022-09-27 | 烟台市和元艾迪斯生物医药科技有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
WO2019157772A1 (zh) * | 2018-02-13 | 2019-08-22 | 和元生物技术(上海)股份有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
CN110152014B (zh) * | 2018-02-13 | 2022-09-27 | 烟台市和元艾迪斯生物医药科技有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
CN108452320B (zh) * | 2018-02-13 | 2020-04-10 | 烟台市和元艾迪斯生物医药科技有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
CN110483639A (zh) * | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
CN110507824A (zh) * | 2018-05-21 | 2019-11-29 | 荣昌生物制药(烟台)有限公司 | 一种抗间皮素抗体及其抗体药物缀合物 |
CN110575547B (zh) * | 2018-06-07 | 2021-07-30 | 中国科学院上海药物研究所 | 靶向于tf的抗体-药物偶联物及其制法和用途 |
CN112442132A (zh) * | 2019-09-05 | 2021-03-05 | 复旦大学 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
WO2022178753A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising targeting moiety binding fragments and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013532148A (ja) * | 2010-06-15 | 2013-08-15 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
JP2019526256A (ja) * | 2015-08-20 | 2019-09-19 | フータン ユニバーシティ | 組織因子を標的とする抗体、その調製方法及びその使用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5589173A (en) * | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1994005328A1 (en) * | 1992-08-28 | 1994-03-17 | The Scripps Research Institute | Inhibition of tumor metastasis via neutralization of tissue factor function |
US7749498B2 (en) * | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20060235209A9 (en) * | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
US7579000B2 (en) * | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
WO2005025623A2 (en) * | 2003-07-28 | 2005-03-24 | Emory University | Ef-24-factor vii conjugates |
EA014900B1 (ru) * | 2005-11-07 | 2011-02-28 | Зе Скрипс Ресеч Инститьют | Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором |
CN101195659A (zh) * | 2006-12-05 | 2008-06-11 | 复旦大学 | 高抗凝活性抗人组织因子单克隆抗体及其制备方法和应用 |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
KR102372245B1 (ko) * | 2013-11-21 | 2022-03-08 | 젠맵 에이/에스 | 항체-약물 접합체 동결건조 제제 |
CN104892763A (zh) * | 2014-03-05 | 2015-09-09 | 中国科学院上海药物研究所 | 抗体-药物偶联物Pertuzumab-MCC-DM1、其与Trastuzumab的组合物及其应用 |
CN106459205B (zh) | 2014-04-11 | 2021-04-09 | 免疫医疗有限责任公司 | 包含半胱氨酸工程化抗体的轭合化合物 |
US10676537B2 (en) * | 2016-08-22 | 2020-06-09 | Fudan University | Antibody targeted to tissue factor, preparation method therefor, and use thereof |
CN110575547B (zh) | 2018-06-07 | 2021-07-30 | 中国科学院上海药物研究所 | 靶向于tf的抗体-药物偶联物及其制法和用途 |
-
2017
- 2017-03-03 CN CN201710125244.6A patent/CN106938051B/zh active Active
- 2017-06-09 EP EP17842668.0A patent/EP3501548A4/en active Pending
- 2017-06-09 WO PCT/CN2017/087779 patent/WO2018036243A1/zh unknown
- 2017-06-09 US US16/326,886 patent/US11534495B2/en active Active
- 2017-06-09 JP JP2019511435A patent/JP7020655B2/ja active Active
-
2022
- 2022-10-27 US US18/050,240 patent/US20230138930A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013532148A (ja) * | 2010-06-15 | 2013-08-15 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
JP2019526256A (ja) * | 2015-08-20 | 2019-09-19 | フータン ユニバーシティ | 組織因子を標的とする抗体、その調製方法及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
US20230138930A1 (en) | 2023-05-04 |
WO2018036243A1 (zh) | 2018-03-01 |
US20190201543A1 (en) | 2019-07-04 |
JP7020655B2 (ja) | 2022-02-16 |
EP3501548A1 (en) | 2019-06-26 |
US11534495B2 (en) | 2022-12-27 |
CN106938051B (zh) | 2019-10-11 |
CN106938051A (zh) | 2017-07-11 |
EP3501548A4 (en) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230138930A1 (en) | Tissue factor-targeted antibody-drug conjugate | |
CA3093327C (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
JP6326137B2 (ja) | 抗her2抗体及びその結合体 | |
US11939386B2 (en) | AXL-targeting antibody, antibody-drug conjugate, preparation method therefor, and use thereof | |
KR20120031265A (ko) | 항메소텔린 면역접합체 및 그의 용도 | |
JP6113717B2 (ja) | 抗cdh3(p−カドヘリン)抗体の薬剤コンジュゲート | |
JP7020656B2 (ja) | 組織因子を標的とする抗体、その調製方法及びその使用 | |
JP2020520672A (ja) | 抗−ヒトインターロイキン−2抗体及びその用途 | |
CN117024590A (zh) | 抗人b7-h3的单克隆抗体及其应用 | |
JP5102612B2 (ja) | B細胞疾患の標的 | |
US9644028B2 (en) | Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof | |
EP4299589A1 (en) | Anti-human cd73 antibody and use thereof | |
US10676537B2 (en) | Antibody targeted to tissue factor, preparation method therefor, and use thereof | |
AU2019219937B2 (en) | Anti-TRAILR2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy | |
CN110152014B (zh) | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 | |
CN116836286A (zh) | 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190423 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210601 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7020655 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |